Inclusion Criteria:

- histologic diagnosis of adenocarcinoma of the prostate with no evidence of metastatic
disease to the nodes, bone or lung

- stage T1a moderately or poorly differentiated, T1b, T1c or T2 by the current UICC-TNM
classification

Exclusion Criteria:

- PSA > 40 mcg/L

- previous therapy for carcinoma of the prostate other than biopsy or TURP, including
patients previously on hormone therapy for treatment of their prostate cancer

- prior or active malignancy other than non-melanoma skin cancer; or colon or thyroid
cancer treated a minimum of five years prior to study entry and presumed cured

- simulated volume exceeds 1000 cm3

- previous pelvic radiotherapy

- inflammatory bowel disease

- serious non-malignant disease which would preclude radiotherapy or surgical biopsy

- geographic inaccessibility for follow-up

- psychiatric or addictive disorder which would preclude obtaining informed consent or
adherence to protocol

- unable to commence radiation therapy within 26 weeks of the date of last prostatic
biopsy

- failure to give informed consent to participate in the study